SCHEMBL80207

SCHEMBL80207

O=C(O)/C=C/c1cccc(C(F)(F)F)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.64
P4HB P07237 2/20 0.64
MEN1 O00255 1/20 0.64
LMNA P02545 1/20 0.64
HSP90AA1 P07900 1/20 0.64
MAPT P10636 1/20 0.64
PKM P14618 1/20 0.64
KMT2A Q03164 1/20 0.64
MAOB P27338 5/20 0.63
L3MBTL1 Q9Y468 2/20 0.58
HTT P42858 1/20 0.58
THRB P10828 1/20 0.58
MAOA P21397 1/20 0.58
KDM4E B2RXH2 2/20 0.57
ALDH1A1 P00352 2/20 0.56
FBP1 P09467 1/20 0.55
HDAC3 O15379 1/20 0.55
TNKS O95271 1/20 0.55
HDAC4 P56524 1/20 0.55
HDAC1 Q13547 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL80208 1.00 NPSR1 (0.64) NPSR1P4HBMEN1LMNAHSP90AA1
SCHEMBL29426408 1.00 NPSR1 (0.64) NPSR1P4HBMEN1LMNAHSP90AA1
SCHEMBL15673342 1.00 NPSR1 (0.64) NPSR1P4HBMEN1LMNAHSP90AA1
Hydrochloric Acid SCHEMBL4095648 0.98 P4HB (0.62) NPSR1P4HBMEN1LMNAHSP90AA1
Ethane SCHEMBL9580381 0.97 P4HB (0.61) NPSR1P4HBMEN1LMNAHSP90AA1
Guanidine SCHEMBL8055577 0.91 NPSR1 (0.56) NPSR1P4HBMEN1LMNAHSP90AA1
SCHEMBL10585234 0.89 P4HB (0.56) NPSR1P4HBMEN1LMNAHSP90AA1
SCHEMBL6781559 0.89 P4HB (0.56) NPSR1P4HBMEN1LMNAHSP90AA1
SCHEMBL20546818 0.88 MAOB (0.55) NPSR1P4HBMEN1LMNAHSP90AA1
SCHEMBL17061419 0.88 P4HB (0.66) NPSR1P4HBMEN1LMNAHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 466 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
US-20180105492-A1 COMPOUNDS DERIVED FROM 3-ALKYLAMINE-1H-INDOLYL ACRYLATE AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO DE LA PRINCESA (ES) 2018-04-19 US claimed
EP-3208262-A1 COMPOUNDS DERIVED FROM 3-ALKYLAMINO-1H-INDOLE ACRYLATE, AND THE USE THEREOF IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Fundación Para La Investigación Biomédica Del Hospital De La Princesa (ES) 2017-08-23 EP claimed
EP-1526584-B1 Method of forming electroluminescent semiconducting nanocrystal patterned layer for an organic-inorganic hybrid electroluminescent devices, and organic-inorganic hybrid electroluminescent device using the same. SAMSUNG ELECTRONICS CO LTD (KR) 2017-06-14 EP claimed
EP-1429768-B1 NOVEL MEDICAMENTS FOR INHALATION BOEHRINGER INGELHEIM PHARMA (DE) 2016-11-16 EP claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 US claimed
US-9217012-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-12-22 US claimed
EP-2403823-B1 PROCESS FOR THE PREPARATION OF CINACALCET AND SALTS THEREOF, AND INTERMEDIATES FOR USE IN THE PROCESS CIPLA LTD (IN) 2015-10-21 EP claimed
US-20060000778-A1 high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers MCMASTER UNIVERSITY (CA) 2006-01-05 US claimed
US-20050256149-A1 Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-11-17 US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-20050161666-A1 Photosensitive semiconductor nanocrystals, photosensitive composition comprising semiconductor nanocrystals and method for forming semiconductor nanocrystal pattern using the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2005-07-28 US claimed
US-6919325-B2 Respiratory system disorders; synergistic mixtures BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-07-19 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
EP-1526584-A2 Photosensitive semiconductor nanocrystals, photosensitive composition comprising semiconductor nanocrystals and method for forming semiconductor nanocrystal pattern using the same Samsung Electronics Co., Ltd (KR) 2005-04-27 EP claimed
EP-1429768-A1 NOVEL MEDICAMENTS FOR INHALATION Boehringer Ingelheim Pharma GmbH & Co.KG (DE) 2004-06-23 EP claimed
US-20030130300-A1 Respiratory system disorders; synergistic mixtures BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-10 US claimed
WO-2003024452-A1 NOVEL MEDICAMENTS FOR INHALATION BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-03-27 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS NPSR1 3502/4885P4HB 698/4885MEN1 4428/4885
US-20050256149-A1 Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts ADRB3, ADRB1, HSD3B1 NPSR1 1297/4885P4HB 4196/4885MEN1 3928/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS NPSR1 3502/4885P4HB 698/4885MEN1 4428/4885
US-20180105492-A1 COMPOUNDS DERIVED FROM 3-ALKYLAMINE-1H-INDOLYL ACRYLATE AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES NFE2L2, KEAP1, HTT NPSR1 2981/4885P4HB 2954/4885MEN1 4629/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 NPSR1 3033/4885P4HB 1168/4885MEN1 1466/4885
US-20030130300-A1 Respiratory system disorders; synergistic mixtures ADRB3, ADRB1, CHRM3 NPSR1 500/4885P4HB 4264/4885MEN1 4709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.